Ποια είναι η τιμή για Sigilon Therapeutics, Inc. (SGTX)

Η τιμή για Sigilon Therapeutics, Inc. (SGTX) είναι $22.47

Ποια είναι η κεφαλαιοποίηση αγοράς για Sigilon Therapeutics, Inc. (SGTX)

Η κεφαλαιοποίηση αγοράς για Sigilon Therapeutics, Inc. (SGTX) είναι $49.76M

Sigilon Therapeutics, Inc. (SGTX) Διαίρεση Μετοχών

Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.